Related Experiment Video
Updated: Oct 26, 2025

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
Published on: September 18, 2017
Electrical Features of the Diabetic Myocardium. Arrhythmic and Cardiovascular Safety Considerations in Diabetes
Mónica Gallego1, Julián Zayas-Arrabal1, Amaia Alquiza1
1Department of Physiology, Faculty of Pharmacy, University of the Basque Country UPV/EHU, Vitoria-Gasteiz, Spain.
Insights
Diabetes causes heart electrical remodeling, prolonging the QT interval and increasing arrhythmia risk. Evaluating QT prolongation is crucial for drug safety and understanding diabetic cardiomyopathy.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia.
- Diabetic cardiomyopathy involves myocardial dysfunction, affecting both mechanical and electrical properties.
- Cardiac electrical remodeling, particularly prolonged ventricular repolarization (QT interval), is a hallmark in diabetic patients.
Purpose of the Study:
- To review the mechanisms of cardiac electrical remodeling in diabetes.
- To discuss the implications of QT prolongation for proarrhythmic risk and sudden death in diabetics.
- To highlight the importance of cardiovascular safety assessments for antidiabetic drugs.
Main Methods:
- Review of existing literature on diabetes, cardiac electrophysiology, and drug safety studies.
- Analysis of cellular mechanisms involving ion channel alterations in the diabetic heart.
- Examination of electrocardiographic findings, specifically QT interval duration.
Main Results:
- Diabetes induces significant cardiac electrical remodeling, leading to prolonged QT intervals.
- Altered ion channel function in diabetic myocardium delays repolarization, increasing arrhythmia susceptibility.
- QT prolongation serves as a marker for proarrhythmic risk, necessitating thorough QT/QTc analysis for new drug approvals.
Conclusions:
- Diabetic cardiomyopathy encompasses electrical abnormalities, notably QT prolongation, elevating the risk of life-threatening arrhythmias.
- Cardiovascular safety evaluations, including QT interval assessment, are essential for antidiabetic medications.
- Some glucose-lowering drugs may offer cardioprotection by mitigating arrhythmia risk.
Abstract:
Diabetes is a chronic metabolic disease characterized by hyperglycemia in the absence of treatment. Among the diabetes-associated complications, cardiovascular disease is the major cause of mortality and morbidity in diabetic patients. Diabetes causes a complex myocardial dysfunction, referred as diabetic cardiomyopathy, which even in the absence of other cardiac risk factors results in abnormal diastolic and systolic function. Besides mechanical abnormalities, altered electrical function is another major feature of the diabetic myocardium. Both type 1 and type 2 diabetic patients often show cardiac electrical remodeling, mainly a prolonged ventricular repolarization visible in the electrocardiogram as a lengthening of the QT interval duration. The underlying mechanisms at the cellular level involve alterations on the expression and activity of several cardiac ion channels and their associated regulatory proteins. Consequent changes in sodium, calcium and potassium currents collectively lead to a delay in repolarization that can increase the risk of developing life-threatening ventricular arrhythmias and sudden death. QT duration correlates strongly with the risk of developing torsade de pointes, a form of ventricular tachycardia that can degenerate into ventricular fibrillation. Therefore, QT prolongation is a qualitative marker of proarrhythmic risk, and analysis of ventricular repolarization is therefore required for the approval of new drugs. To that end, the Thorough QT/QTc analysis evaluates QT interval prolongation to assess potential proarrhythmic effects. In addition, since diabetic patients have a higher risk to die from cardiovascular causes than individuals without diabetes, cardiovascular safety of the new antidiabetic drugs must be carefully evaluated in type 2 diabetic patients. These cardiovascular outcome trials reveal that some glucose-lowering drugs actually reduce cardiovascular risk. The mechanism of cardioprotection might involve a reduction of the risk of developing arrhythmia.
More Related Videos
Related Concept Videos
Mechanism of Cardiac Arrhythmias
Dysrhythmias I: Introduction
Dysrhythmias V: Evaluating Dysrhythmias
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Dysrhythmias VII: Nursing Management of Dysrhythmias

